Study: Hemp Seed Oil Associated With Improved Clinical and Immunological Parameters In Multiple Sclerosis PatientsMay 24, 2013
The consumption of legal hemp seed nutritional oil, in conjunction with the intake of evening primrose oils and a restricted diet high in Hot-natured foods (such as pepper) and low in saturated fats and sugars, is associated with “significant improvement” in symptom management and immunological characteristics in subjects with multiple sclerosis, according to clinical trial data published this month in the scientific journal BioImpacts.
Researchers at Tabriz University of Medical Sciences in Iran assessed the impact of hemp seed oil, evening primrose oils, and a restricted diet for a period of six months in 23 patients diagnosed with relapsing remitting MS. Researchers reported that participants at the study’s completion “were healthier in comparison to baseline,” concluding that “clinical and immunological parameters showed improvement in the patients after the intervention.” They noted that hemp seed oil possesses potent antioxidative properties and also likely acts on specific signaling pathways that regulate inflammatory responses — two characteristics that would presumably make it beneficial in the treatment of MS.
Authors concluded: “After 6 months, significant improvements in extended disability status score were found. … [O]ur study demonstrates for the first time in the literature a decrease in both clinical and pro- inflammatory disease activity in MS patients during periods of dietary intervention. Our data demonstrated that co-supplemented hemp seed and evening primrose oils with Hot-natured diet intervention may decrease the risk of developing MS.”
Previously published clinical trials assessing the impact of inhaled cannabis and extracted organic cannabinoids in patients with MS have demonstrated that plant cannabinoids can alleviate disease symptoms — such as involuntary spasticity, neuropathy, and bladder dysfunction — and, in some subjects, may actually moderate disease progression. Nonetheless, the National MS Society shares little enthusiasm for cannabis or cannabis-derived products as a therapeutic option for MS patients, stating on its website: “[B]ased on the studies to date — and the fact that long-term use of marijuana may be associated with significant, serious side effects — it is the opinion of the National Multiple Sclerosis Society’s Medical Advisory Board that there are currently insufficient data to recommend marijuana or its derivatives as a treatment for MS symptoms.”
DFW NORML proudly presents the Texas Regional NORML Conference at the Norris Conference Center (304 Houston St. Fort Worth, Texas 76102-7404) in downtown Fort Worth from June 7 – 9. This historic event includes over a dozen speakers such as Keith Stroup, founder of NORML, Judge Jim Gray, the 2012 Libertarian Party Vice Presidential Nominee, expert cultivation and concentrate tips, medicinal alternatives to smoking, an exclusive screening of the new documentary American Drug War 2: Cannabis Destiny, patient testimonials, a hemp fashion show, reception and live art show, two after parties, vendors, prizes and more than a few surprises.
The primary goals for the Texas Regional NORML Conference are:
1.) Give Texans an honest, entertaining and interactive cannabis education.
2.) Showcase the strength of the Texas effort to end prohibition.
3.) Call all Texans to action because now is the time to get involved!
This historic event includes over a dozen speakers including Keith Stroup, founder of NORML, an exclusive screening of the new documentary American Drug War 2: Cannabis Destiny, expert cultivation and concentrate tips, a hemp fashion show, reception and live art show, two after parties, vendors, prizes and more than a few surprises.
Get your 3 Day pass for a $100 donation which includes all days of the conference, the reception, both after parties and a swag bag full of goodies provided by our generous sponsors. Discounted pricing available for students, seniors, veterans, media and NORML chapters.
The deadline for online registration of the Texas Regional NORML Conference is 6/7. Otherwise, you can register in person 6/7 – 6/9 for the same price!
(Click the names with links to view short videos with the speakers)
- Judge Jim Gray, 2012 Libertarian Party Vice Presidential Nominee and author of“Why Our Drug Laws Have Failed and What We Can Do About It”
- Keith Stroup, Founder & Legal Counsel at NORML
- “Radical” Russ Belville of 420radio.org
- Mike Hyde – Founder of the Cash Hyde Foundation and father of Cash Hyde
- Cheyanne Weldon, Executive Director of Texas NORML
- Shaun McAlister, Executive Director of DFW NORML
- Erik Altieri, Communications Director & Chapter Coordinator for NORML
- Jamie Balagia – Public Information Officer and Attorney at San Antonio NORML
- Joy Strickland – Founder of Mothers Against Teen Violence
- Clif Deuvall – Co-chair of Texas at US Marijuana Party of Texas, Chairman at Texas Cannabis Party and Founder Norml of Waco Inc. at NORML
- Leslie Burgoyne, DFW NORML Family Law Attorney
- Reverend Russell Elleven – Unitarian Universalist Minister
- Derek Cross – Author at Hemp Healthy Today
- Allen Patterson – Chairman of the Tarrant County Libertarian Party
- Larry Talley – Strategist for DFW NORML, speaker for Law Enforcement Against Prohibition and retired US Navy
- Terry Nelson – Executive Board Member at Law Enforcement Against Prohibition (LEAP), former Border Patrol agent and Homeland Security Supervisor
- Toni Ann Hanskett-Mills – Patient Advocate for Medical Cannabis Patients with 28 yrs experience in Direct Patient Care
- Stephen Betzen – Founder of the Texas Coalition for Compassionate Care
- Margarita McAuliffe – Students for Sensible Drug Policy and Texas Moms United
Hope to see you in Texas soon!
Senator Ron Wyden has introduced an amendment to Senate Bill 3240, the Senate version of this year’s federal farm bill, that requires the federal government to respect state laws allowing the cultivation of industrial hemp. Hemp is a distinct variety of the plant species cannabis sativa that contains only trace (less than one percent) amounts of tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis.
The amendment language mimics the “Industrial Hemp Farming Act of 2013,” which remains pending as stand-alone legislation in both the House and Senate but has yet to receive a legislative hearing. Senator Wyden’s provision to the Senate’s Farm Bill amends the Controlled Substances Act to exclude industrial hemp from the definition of marijuana. The measure grants state legislatures the authority to license and regulate the commercial production of hemp as an industrial and agricultural commodity.
“For me, what’s important is that people see, particularly in our state, there’s someone buying it at Costco in Oregon,” Senator Wyden previously stated in support of this Act, “I adopted what I think is a modest position, which is if you can buy it at a store in Oregon, our farmers ought to be able to make some money growing it.”
Eight states – Colorado, Maine, Montana, North Dakota, Oregon, Vermont, Washington, and West Virginia – have enacted statutory changes defining industrial hemp as distinct agricultural product and allowing for its regulated commercial production. Passage of this amendment would remove existing federal barriers and allow these states and others the authority to do so without running afoul of federal anti-drug laws.
Senator Wyden’s amendment is co-sponsored by Sen. Jeff Merkley (D-OR), Sen. Rand Paul (R-KY), and Senate Minority Leader Mitch McConnell (R-KY). Senator Patrick Leahy (D-VT) has also expressed his support for this proposal.
According to a Congressional Research Service report, “The United States is the only developed nation in which industrial hemp is not an established crop.”
Click here to quickly and easily contact your Senator in support of industrial hemp.
Members of the New Hampshire Senate voted 18 to 6 today in favor of an amended version of House Bill 573, which allows for the physician-authorized use and state-licensed dispensing of cannabis to qualified patients. House lawmakers had previously voted 286 to 64 in March in favor of a broader version of the bill.
As amended by the Senate, HB 573 would establish up to four state-sanctioned marijuana dispensing facilities. (The House version allowed for up to five facilities.) State-qualified patients would be allowed to possess up to two ounces of cannabis, but they would only be legally able to obtain it from a state-licensed dispensary. (The House version of the bill provided provisions for home cultivation.) Under the amended bill, patients lacking a state-issued identification card would not be permitted to raise an affirmative defense, meaning that patients who could benefit immediately from the therapeutic use of cannabis will be forced to wait several months until after the bill’s passage in order to obtain the necessary paperwork to receive any legal protection under the law. The Senate also voted to eliminate post-traumatic stress from the list of authorized conditions for which a physician could legally recommend marijuana therapy.
The measure also stipulates that qualified patients must possess a preexisting relationship with their physician (of at least 90 days) and that they have previously pursued conventional remedies to treat their condition.
Newly-elected Democrat Gov. Maggie Hassan had voiced her opposition to several elements of the House version, which spurred the Senate to adopt several changes.
The Senate version of the bill now goes back to the House, whose members will either sign off on or, more likely, reject the Senate’s amendments. The latter action would create the need for a “committee of conference,” at which time a special committee of House representatives and senators will compromise on a final version of the bill. That language will then be forwarded to the governor’s desk.
If you reside in New Hampshire, there is still time to contact the Governor’s office and urge her to rethink her position on these controversial Senate amendments. Tell her that these Senate provisions will hurt, not help, patients in New Hampshire. Implore her that seriously ill patients can not wait years for for dispensaries to become available and that they require a home grow alternative. You can call the Governor’s office or use NORML’s ‘Act’ page here.
Finally, House Bill 573 co-sponsor, Rep. Donald “Ted” Wright, has launched a Change.org petition urging Gov. Hassan to amend her position. Whether or not you reside in New Hampshire, please sign the petition and share it with your friends and colleagues.
For information on how you can support pending marijuana law reform legislation in other states, please visit here.
A Michigan traffic safety law that prohibits the operation of a motor vehicle by persons who possess any presence of THC in their blood, regardless of whether or not they are behaviorally impaired by the substance, may not be strictly applied to state-qualified medical cannabis patients. So decided the Michigan Supreme Court on Tuesday in the case People v Koon.
In a unanimous opinion, the Court determined that legal protections extended to state-qualified patients under the Michigan Medical Marihuana Act, enacted by voters in 2008, supersede the state’s zero tolerance, internal possession law. As a result, the Court determined that state prosecutors must establish that authorized patients charged under the statute are actually impaired by their cannabis use in order to gain a DUI criminal conviction.
According to the syllabus of the Opinion:
“The MMMA [Michigan Medical Marihuana Act] does not define what it means to be ‘under the influence,’ but the phrase clearly contemplates something more than having any amount of marijuana in one’s system and requires some effect on the person. Thus, the MMMA’s protections extend to a registered patient who internally possesses marijuana while operating a vehicle unless the patient is under the influence of marijuana. The immunity from prosecution provided under the MMMA to a registered patient who drives with indications of marijuana in his or her system but is not otherwise under the influence of marijuana inescapably conflicts with MCL 257.625(8) [the state's zero tolerance per se DUI law], which prohibits a person from driving with any amount of marijuana in her or system.”
The state’s zero tolerance per se drug law remains applicable to non-patients. Under such laws, motorists are guilty per se (in fact) of a criminal traffic safety violation if they engage in the act of driving while detectable levels of certain controlled substances or, in some cases, their inert metabolites (byproducts) are present in the defendants’ blood or urine. Proof of actual impairment is not a requirement for a conviction under the law.
To date, ten states — Arizona, Delaware, Georgia, Illinois, Indiana, Iowa, Michigan, Rhode Island, Utah, and Wisconsin — have enacted legislation imposing zero tolerance per se thresholds for the presence of cannabinoids and/or their metabolites. (State-authorized medical cannabis patients in Arizona and Rhode Island are exempt from prosecution under these per se statutes unless the state can provide additional evidence of psychomotor impairment.)
Five additional states impose non-zero-tolerant per se thresholds for cannabinoids in blood: Montana (5ng/ml — law takes effect on October 1, 2013), Pennsylvania (1ng/ml), Ohio (2ng/ml), Nevada (2ng/ml) and Washington (5ng/ml). Most recently, Colorado lawmakers approved legislation stating that the presence of THC/blood levels above 5ng/ml “gives rise to permissible inference that the defendant was under the influence.” State-qualified patients in Colorado, Montana, and Nevada are not provided legal exemptions from these statutes, although legislation is presently pending in Nevada to do so.
Such caution is similarly expressed by the United States National Highway Transportation and Safety Administration, which acknowledges: “It is difficult to establish a relationship between a person’s THC blood or plasma concentration and performance impairing effects. … It is inadvisable to try and predict effects based on blood THC concentrations alone.”
A 2013 review of per se drugged driving laws and their impact on road safety found “no evidence that per se drugged driving laws reduce traffic fatalities.”